Navigation Links
NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
Date:11/21/2007

SOPHIA ANTIPOLIS, France, November 21 /PRNewswire-FirstCall/ -- Michele Garufi, Chairman and CEO of NicOx (Eurolist: COX), will provide an update on the progress of the Company's research and development programs and the status of ongoing alliances at three financial conferences in New York during the week of November 26, 2007:

- At the 19th Annual Piper Jaffray Health Care Conference on November 28 at 15:00 US Eastern Time (21:00 Central European Time - 20:00 UK Time) at the Pierre New York Hotel. To access the live audio broadcast of the presentation or its subsequent archived recording please logon to http://www.nicox.com. Please connect to the website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

- At the Lazard Capital Markets 4th Annual Health Care conference on November 27th at 14:00 US Eastern Time (20:00 Central European Time - 19:00 UK Time) at the New York Palace Hotel (no live audio broadcast or archived recording of the presentation will be available).

- In addition, NicOx will participate in the Natixis Securities Mid-Cap Euro Healthcare Seminar on November 29 at the Warwick Hotel.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) (OTC: NICXF) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of pain and inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes.

NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer Inc. and Merck and Co., Inc.

NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of EuronextTM Paris (segment: Next Economy).

The elements included in this communication may contain forward-looking statements subject to certain risks and uncertainties. Actual results of the company may differ materially from those indicated in the forward-looking statements because of different risks factors described in the company's document de reference.

CONTACTS: http://www.nicox.com

NicOx:

Karl Hanks - Manager of Corporate Relations and Market Analysis -

Tel +33-(0)4-97-24-53-42 - hanks@nicox.com

Investors in the United States

Burns McClellan:

Lisa Burns - Tel +1-212-213-0006 - lburns@burnsmc.com

Juliane Snowden - jsnowden@burnsmc.com

Media in the United States

FD - Jonathan Birt -

Tel +1-212-850-56-34 - jbirt@fd-us.com

Media in Europe -

Citigate Dewe Rogerson:

Valerie Auffray -

Tel: +44-(0)207-282-2979 - valerie.auffray@citigatedr.co.uk

David Dible -

Tel +44-(0)207-282-2949 - david.dible@citigatedr.co.uk


'/>"/>
SOURCE NicOx
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NicOx Opens U.S. Headquarters in New Jersey
2. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
3. Avicena Group to Present at Noble Financial Conference
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CEL-SCI to Present at the Noble Financial Conference
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Strategic Diagnostics Updates Roth Conference Presentation Time
11. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
Breaking Biology News(10 mins):